Reimbursement Briefs: Medicare Part B, PCORI Research
This article was originally published in The Pink Sheet Daily
Executive Summary
MedPAC will analyze alternatives for Medicare Part B to use “least costly alternative” payment method in lieu of legislative authority; OIG says Part B dispensing fees are too high; PCORI releases draft proposal on research review.
You may also be interested in...
Biosimilars Add “Urgency” To Medicare Payment Reforms – MedPAC Commissioner
Developing alternatives to the ASP-based reimbursement system for Medicare Part B drugs may become increasingly important to ensure the program will benefit from lower-cost biosimilars, Georgetown’s Jack Hoadley points out.
Medicare Part B Drug "Least Costly Alternative" Policy Rescinded By CMS
The Centers for Medicare and Medicaid Services has officially notified its contractors to stop using an option to limit payments for Medicare Part B drugs to the "least costly alternative" in a therapeutic class
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.